Dan Hertz joined the Department of Clinical Pharmacy in the College of Pharmacy in April 2013. He received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University and his PhD in pharmaceutical sciences from the University of North Carolina Eshelman School of Pharmacy.

Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of paclitaxel in breast cancer. The approaches being developed include identifying an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes. He uses several approaches to discover and validate the effect of common variants on drug exposure or patient sensitivity to toxicity. Much of this work is conducted through his membership in oncology cooperative groups, which provide access to sufficiently large patient cohorts for definitive analyses. 

Research Interests

  • Developing tools for individualizing cancer treatments

  • Understanding the role of patient genetics in treatment outcomes

  • Translating genetic associations into clinical practice to improve patient care

Selected Publications